Liminal BioSciences Inc.
NASDAQ: LMNL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bruce Pritchard BA, CA, FIOD
- Employees
- 251
- Headquarters
- Laval, Canada
- IPO year
- 2009
- Market cap
- $27.6M
- Website
- https://www.liminalbiosciences.com
Loading LMNL…
Loading profile data…Frequently asked questions about LMNL
What does Liminal BioSciences Inc. (LMNL) do?
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identifie...
Where does LMNL trade?
Liminal BioSciences Inc. (LMNL) trades on the NASDAQ Global Market.
What sector is LMNL in?
Liminal BioSciences Inc. (LMNL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Liminal BioSciences Inc.?
Bruce Pritchard BA, CA, FIOD is the chief executive officer of Liminal BioSciences Inc. (LMNL).
Where is Liminal BioSciences Inc. headquartered?
Liminal BioSciences Inc. is headquartered in Canada.
Does LMNL pay a dividend?
Liminal BioSciences Inc. (LMNL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LMNL go public?
Liminal BioSciences Inc. (LMNL) completed its initial public offering in 2009.